British American Tobacco p.l.c 6-K, filed Oct 13, 2023
British American Tobacco p.l.c. (BTI)
6-K
2023-10-13
For: 2023-10-13
View Original
Added on
April 08, 2026
About this 6-K
British American Tobacco p.l.c filed this 6-K on October 13, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
October 13, 2023
Commission File Number: 001-38159
BRITISH AMERICAN TOBACCO P.L.C.
(Translation of registrant’s name into English)
Globe House
4 Temple Place
London WC2R 2PG
United Kingdom
(Address of principal executive office)
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
This report includes materials as exhibits that have been published and made available by British American Tobacco p.l.c. (the “Registrant”) as of October 13, 2023.
The information contained in this Form 6-K is incorporated by reference into the Form S-8 Registration Statements File Nos. 333-223678, 333-219440 and 333-237186 of the Registrant and into the Form F-3 Registration
Statement File Nos. 333-265958, 333-265958-01, 333-265958-02, 333-265958-03, 333-265958-04 and 333-265958-05 of the Registrant, British American Tobacco Holdings (The Netherlands) B.V., Reynolds American Inc., B.A.T.
Netherlands Finance B.V., B.A.T. International Finance p.l.c. and B.A.T Capital Corporation, and related Prospectuses, as such Registration Statements and Prospectuses may be amended from time to time.
EXHIBIT INDEX
|
Exhibit
|
|
Description
|
| |
||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
British American Tobacco p.l.c.
|
||||
|
|
By:
|
/s/ Claire Dhokia
|
||
| Name: |
Claire Dhokia | |||
| Title: |
Deputy Company Secretary |
|||
Date: October 13, 2023
Exhibit 1
British American Tobacco p.l.c. (the “Company”)
13 October 2023
BAT Appoints Chief People Officer to the Management Board
Further to the changes to the Management Board announced on 19 June 2023, Cora Koppe-Stahrenberg, has been appointed to the new role of Chief People Officer and will join the BAT Management Board with effect from 1
November 2023.
Bringing critical experiences from other sectors and industries, Cora was most recently Global Head of Human Resources of Fresenius Medical Care, a publicly listed global healthcare company with over 125,000 employees.
While at Fresenius Medical Care, Cora established a new Global HR function, and implemented a global people strategy which focused on the creation of a collaborative and empowering culture delivered through a number of change initiatives. Previously,
Cora held various international senior HR positions at Marsh & McLennan Companies, Emirates Investment Authority, and General Electric.
Tadeu Marroco, Chief Executive, commented:
“I am delighted to welcome Cora to the Management Board. This is a significant management team enhancing appointment for BAT. Culture and collaboration are at the heart of my leadership
agenda, Cora shares these values and will play a key role in the Group’s transformation to build A Better Tomorrow. I have no doubt that Cora will bring a fresh perspective having worked internationally in multiple sectors outside our industry and
will bring new insights and capability to our management team.
“I look forward to working with Cora to deliver a winning culture and a dynamic, modern BAT.”
The Chief People Officer will report to the Chief Executive.
ENDS
Enquiries
Media Centre
+44 (0) 20 7845 2888 (24 hours) | @BATplc
Investor Relations
Victoria Buxton: +44 (0)20 7845 2012
Amy Chamberlain: +44 (0)20 7845 1124
Yetunde Ibe: +44 (0)20 7845 1095
John Harney: +44 (0)20 7845 1263
Jane Henderson: +44 (0)20 7845 1117
About BAT
BAT is a leading, multi-category consumer goods business with a purpose to build A Better Tomorrow™ by reducing the health impact of its business through offering a greater choice of enjoyable and less risky
products for adult consumers.
We continue to be clear that combustible cigarettes pose serious health risks, and the only way to avoid these risks is not to start or to quit. BAT encourages those who would otherwise continue to smoke to switch
completely to scientifically-substantiated, reduced-risk alternatives*†. In order to deliver this, BAT is transforming into a truly consumer-centric multi-category consumer products business.
BAT’s ambition is to have 50 million consumers of its non-combustible products by 2030 and to generate £5billion of New Categories revenue by 2025. BAT has set stretching ESG targets including achieving carbon
neutrality for Scopes 1 & 2 by 2030 and eliminating unnecessary single-use plastic and making all plastic packaging reusable, recyclable or compostable by 2025.
BAT employs over 50,000 people. The BAT Group generated revenue of £27.65 billion in 2022 and profit from operations of £10.5 billion.
The company’s Strategic Portfolio is made up of its global cigarette brands and a growing range of reduced-risk*† New Category tobacco and nicotine products and traditional non-combustible tobacco products. These
include vapour, tobacco heating products, modern oral products including tobacco-free nicotine pouches, as well as traditional oral products such as snus and moist snuff. In 2022, we had 22.5 million consumers of our non-combustible products, a rise
of 4.2 million on full year 2021.
References in this statement to ‘BAT’, ‘we’, ‘us’ and ‘our’ refer to the British American Tobacco Group.
* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
† Our vapour product Vuse (including Alto, Solo, Ciro and Vibe), and certain products, including Velo, Grizzly, Kodiak, and Camel Snus, which are sold in the U.S., are subject to FDA
regulation and no reduced-risk claims will be made as to these products without agency clearance.
Forward-looking statements
This release contains certain forward-looking statements, including “forward-looking” statements made within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.
These statements are often, but not always, made through the use of words or phrases such as “believe,” “anticipate,” “could,” “may,” “would,” “should,” “intend,” “plan,” “potential,” “predict,” “will,” “expect,” “estimate,” “project,” “positioned,”
“strategy,” “outlook”, “target” and similar expressions. These include statements regarding our customer target ambition, New Categories revenue targets and our ESG targets.
All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. It is believed that the expectations reflected in
this release are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated. A review of the reasons why actual results and developments may differ materially
from the expectations disclosed or implied within forward-looking statements can be found by referring to the information contained under the headings “Cautionary Statement” and “Group Principal Risks” in the 2022 Annual Report and Form 20-F of
British American Tobacco p.l.c. (BAT PLC).
Additional information concerning these and other factors can be found in BAT PLC’s filings with the U.S. Securities and Exchange Commission (“SEC”), including the
Annual Report on Form 20-F and Current Reports on Form 6-K, which may be obtained free of charge at the SEC’s website, http://www.sec.gov and BAT PLC’s Annual Reports, which may be obtained free of charge from the BAT website www.bat.com.
Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser. The forward-looking statements reflect knowledge and
information available at the date of preparation of this release and BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to
place undue reliance on such forward-looking statements.